NEW YORK (GenomeWeb) – Building on an earlier test it developed for diagnosing multiple myeloma, Rotterdam, the Netherlands-based SkylineDx has now partnered with a couple of European institutes and a patient advocacy organization to pursue development of a tool that may be able to guide therapy selection for these cancer patients.
SkylineDx Follows Multiple Myeloma MDx With Collaborative Effort to Develop Therapy Selection Assay
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.